CSClémence Schmitt

Clémence Schmitt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Clémence Schmitt has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phosphoglycolate phosphatase homologs act as glycerol-3-phosphate phosphatase to control stress and healthspan in C. elegans

    by Elite Possik, Clémence Schmitt, Anfal Al-Mass, Ying Bai, Laurence Côté, Johanne Morin, Heidi Erb, Abel Oppong, Wahab Kahloan, J. Alex Parker, et al.

    Metabolic stress due to nutrient excess and lipid accumulation is at the root of many age-associated disorders and the identification of therapeutic targets that mimic the beneficial effects of calorie restriction has clinical importance. Here, using C. elegans as a model organism, we study the roles of a recently discovered enzyme at the heart of metabolism in mammalian cells, glycerol-3-phosphate phosphatase (G3PP) (gene name Pgp) that hydrolyzes glucose-derived glycerol-3-phosphate to glycerol. We identify three Pgp homologues in C. elegans (pgph) and demonstrate in vivo that their protein products have G3PP activity, essential for glycerol synthesis. We demonstrate that PGPH/G3PP regulates the adaptation to various stresses, in particular hyperosmolarity and glucotoxicity. Enhanced G3PP activity reduces fat accumulation, promotes healthy aging and acts as a calorie restriction mimetic at normal food intake without altering fertility. Thus, PGP/G3PP can be considered as a target for age-related metabolic disorders.


  • Suppression of ABHD6 Promotes Healthy Expansion of Adipose Tissue in Obesity

    by Pegah Poursharifi, Clémence Schmitt, Sara-Ivana Calce, Covida Mootoosami, Jonathan Shea, Anfal Al-Mass, Isabelle Chenier, Marie-Line Peyot, André Tchernof, S.R. Murthy Madiraju, et al.

  • Open Access

    Suppression of ABHD6 Promotes Healthy Expansion of Adipose Tissue in Obesity

    by Pegah Poursharifi, Clémence Schmitt, Sara‐Ivana Calce, Covida Mootoosami, Jonathan Shea, Anfal Al‐Mass, Isabelle Chenier, Marie‐Line Peyot, André Tchernof, S.R. Murthy Madiraju, et al.

    The mode of white adipose tissue (WAT) expansion in response to positive energy balance greatly impacts obesity‐related metabolic abnormalities. Pathologic WAT remodeling, characterized by adipocyte hypertrophy and reduced differentiation capacity, results in chronic inflammation, ectopic fat accumulation and insulin resistance. Conversely, healthy adipogenesis is characterized by adipocyte hyperplasia, reduced inflammation and limited fat spill‐over in other organs. Pan‐deletion of the monoacylglycerol lipase alpha/beta hydrolase domain‐6 (ABHD6) demonstrated the therapeutic potential of ABHD6 inhibitors against obesity and type‐2‐diabetes. However, the role of ABHD6 in diet‐induced adipogenesis and adipose inflammation remains unexplored. Here we present evidence, employing pharmacological and genetic approaches, that ABHD6 suppression maintains AT immunometabolic health during high fat diet (HFD)‐induced obesity. ABHD6 expression increases in mouse adipocytes during differentiation, and correlates with the adiposity in WAT of HFD‐fed mice and in visceral fat of patients with obesity. Treatment of adipocytes with the ABHD6 inhibitor (KT203) prior to induction of differentiation increases the expression of adipogenic markers and the number of smaller lipid droplets. In addition, ABHD6 deletion in mice enhances differentiation capacity of primary inguinal pre‐adipocytes. HFD‐fed whole‐body ABHD6‐KO mice exhibit lower expression of proinflammatory cytokines, and less fibrosis and hypoxia parameters in all fat depots. Proinflammatory M1 macrophages in the visceral and brown fat depots are also reduced in HFD‐fed KO mice. Furthermore, the stromal vascular fraction from WAT of HFD‐fed KO mice display reduced glycolytic and increased oxidative rates. Interestingly, other tissues of KO mice, including liver, heart and spleen, show reduced weight, decreased proinflammatory markers and lower fat content, compared to wild type mice on HFD. The results suggest that inhibition/deletion of ABHD6 in HFD fed mice enhances AT capacity to recruit new fat cells through differentiation of pre‐adipocytes, reduces lipid spill‐over in other organs and ameliorates inflammation. These findings provide insight into the role of ABHD6 in the immunometabolic pathways during WAT expansion, and suggest ABHD6 as a therapeutic target for inflammation and obesity‐related complications.